Promoter holding
64.27%
AP
Aurum Pharmaceuticals Private Limited - Due diligence report
A 360° intelligence report on Aurum Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, grow…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Aurum Pharmaceuticals Private Limited — 360° Intelligence Report
Generated from MCA filings & public records77/100
Trust Score
Low Risk
Aurum Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 77/100. Aurum Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 1961, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 25 Jul 2026 from the latest processed filings. Aurum Pharmaceuticals Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
48/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 65/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 38%).
- Profitable - internal accruals available.
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 48/100 Caution Indicated
- Company status is Active as per MCA.
- Marked ACTIVE non-compliant (INC-22A).
- Last balance sheet is for Mar 2020 - filings overdue.
- Litigation present in 1 court forum(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ASHOK DAMODARDAS BHUTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NEHA RAJIV SHANGHVI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NARESH DAMODARDAS BHUTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
06
Ownership & Group Intelligence
As per FY 2020 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 50 · Distress 80
Growth signals & trust indicators
Profit expanded 1.42 year-on-year.
Operating for 65+ years.
Distress signals & risk flags
Statutory filings appear overdue.
Compliance score is weak (48/100).
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence66/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view71/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 8 events17 Sep 2021
Director ceased
NEHA RAJIV SHANGHVI
30 Sep 2020
Last AGM held
Annual general meeting
31 Mar 2020
Latest balance sheet
Filed with ROC
25 Jun 2018
Director appointed
NEHA RAJIV SHANGHVI (Director)
17 Sep 2015
Director ceased
DAMODARDAS BHAIDAS BHUTA
01 Apr 1990
Director appointed
ASHOK DAMODARDAS BHUTA (Director)
01 Jun 1969
Director appointed
NARESH DAMODARDAS BHUTA (Director)
30 Jun 1961
Incorporated
Registered with Roc Mumbai I
10
Key Observations
Auto-generated from the data aboveRevenue declined 2.1x over the last 4 financial year(s).
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
| Company | CIN | Location |
|---|---|---|
| Vixen Pharmaceuticals Private Limited | U74999HR2017PTC070308 | Kaithal, Haryana, India |
| Baldwin Pharmaceuticals Private Limited | U52100JK2015PTC004504 | Jammu, Jammu & Kashmir, India |
| Shellcure Pharmaceuticals Private Limited | U85100PN2015PTC153620 | Pune, Maharashtra, India |
| Intelliscend Nddr Private Limited | U24230MH2019PTC323470 | Thane, Maharashtra, India |
| Baidyanath Enterprises Limted | U32301UP1995PLC018614 | Uttar Pradesh, Uttar Pradesh, India |
| Lifesaver Pharma Private Limited | U74140HR2015PTC055070 | Haryana, Haryana, India |
| Carnegie Pharmaceuticals India Private Limited | U74999PB2018FTC048047 | Amritsar, Punjab, India |
| Avdhoot Pharma Private Limited | U85320GJ2019PTC105981 | Vadodara, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Aurum Pharmaceuticals Private Limited before audits and certifications: compliance score 48/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Aurum Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 50/100, margin trends, ownership structure and peer set for Aurum Pharmaceuticals Private Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Aurum Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Aurum Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Aurum Pharmaceuticals Private Limited an active company?
Aurum Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 48/100 (Caution Indicated).
Is Aurum Pharmaceuticals Private Limited financially healthy?
Aurum Pharmaceuticals Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Aurum Pharmaceuticals Private Limited?
Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Aurum Pharmaceuticals Private Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Aurum Pharmaceuticals Private Limited have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Aurum Pharmaceuticals Private Limited up to date with its ROC filings?
Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 48/100 (Caution Indicated).
Is it risky to lend to Aurum Pharmaceuticals Private Limited?
Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
